Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Historical Valuation Ratios (Summary)

Johnson & Johnson, historical price multiples (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Price to earnings (P/E)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The valuation ratios exhibit varied trends over the observed period. Initial values generally decreased through the end of 2022, followed by significant fluctuations and, in some cases, increases into 2025. A notable divergence in trends is apparent between the Price to Earnings (P/E) ratio and the other ratios analyzed.

Price to Earnings (P/E) Ratio
The P/E ratio began at 23.95 and decreased to 22.97 by December 2022. A substantial increase occurred in early 2023, peaking at 33.43 and 33.35 in April and July, respectively. A dramatic decline followed, reaching a low of 10.12 in October 2023 before stabilizing around 10-11 in the subsequent quarters. From December 2024, the ratio has shown an upward trend, reaching 21.66 by December 2025. This indicates a significant shift in investor sentiment or earnings expectations over the period.
Price to Operating Profit (P/OP) Ratio
The P/OP ratio demonstrated a consistent, though moderate, decline from 21.06 in April 2022 to 17.62 in December 2022. It experienced a slight recovery in the first half of 2023, but remained relatively stable between 15.69 and 19.04 through September 2024. A more pronounced increase is observed in the latter part of the period, rising to 22.95 by December 2025. This suggests a strengthening relationship between price and operating profitability.
Price to Sales (P/S) Ratio
The P/S ratio followed a similar downward trajectory to the P/OP ratio through December 2022, decreasing from 5.00 to 4.34. It exhibited more volatility in 2023, with a peak of 4.84 in July. The ratio remained relatively stable between 4.01 and 4.55 for much of 2024. A clear upward trend emerges in the final quarters, increasing to 6.16 by December 2025, indicating investors are willing to pay more for each dollar of sales.
Price to Book Value (P/BV) Ratio
The P/BV ratio decreased from 6.36 in April 2022 to 5.37 in December 2022. It experienced fluctuations in 2023, with a low of 4.92 in October. The ratio generally trended upward from late 2024, reaching 7.12 by December 2025. This suggests a changing perception of the company’s net asset value relative to its market price.

Overall, the observed ratios suggest a period of shifting valuation dynamics. The significant changes in the P/E ratio, coupled with the more moderate movements in the other ratios, indicate potential changes in earnings expectations or broader market conditions. The increases observed in all ratios towards the end of the period may reflect renewed investor confidence or a reassessment of the company’s growth prospects.


Price to Earnings (P/E)

Johnson & Johnson, historical P/E calculation (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Net earnings (loss) (in millions)
Earnings per share (EPS)2
Share price1, 3
Valuation Ratio
P/E ratio4
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
EPS = (Net earnings (loss)Q4 2025 + Net earnings (loss)Q3 2025 + Net earnings (loss)Q2 2025 + Net earnings (loss)Q1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.

4 Q4 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

5 Click competitor name to see calculations.


The price-to-earnings (P/E) ratio exhibited considerable fluctuation over the analyzed period, spanning from April 2022 to December 2025. Initial values indicated a relatively stable P/E ratio in the range of 22.97 to 24.98. However, a notable increase occurred in the spring of 2023, reaching 33.43 before declining sharply in the subsequent quarter.

Initial Period (Apr 2022 - Dec 2022)
The P/E ratio remained within a narrow band, fluctuating between approximately 23 and 25. This suggests a consistent market valuation relative to earnings during this timeframe. There were no significant peaks or troughs.
Significant Fluctuation (Apr 2023 - Jun 2024)
A substantial increase in the P/E ratio was observed in April 2023, peaking at 33.43. This was followed by a dramatic decrease to 10.12 in October 2023, indicating a significant shift in investor sentiment or earnings expectations. The ratio then experienced moderate volatility, ranging from approximately 9.46 to 10.73, before rising again to 27.19 by September 2024.
Recent Trend (Sep 2024 - Dec 2025)
From September 2024 through December 2025, the P/E ratio demonstrated an upward trend. Starting at 27.19, it increased to 21.66 and then to 240.86 by the end of the period. This suggests increasing investor confidence or expectations of future earnings growth. The final value represents a substantial increase compared to the earlier periods.

The observed changes in the P/E ratio correlate with fluctuations in both share price and earnings per share. The sharp decline in October 2023 coincided with a substantial increase in earnings per share, suggesting the market may have anticipated this improvement and adjusted the share price accordingly. The recent increase in the P/E ratio, particularly in the latter half of 2025, appears to be driven by a combination of rising share price and continued earnings growth.

Overall, the P/E ratio demonstrates a dynamic relationship with underlying financial performance, reflecting shifts in market perception and investor expectations. The period from April 2023 to December 2025 was characterized by greater volatility than the earlier period, culminating in a significantly elevated P/E ratio at the end of the observation window.


Price to Operating Profit (P/OP)

Johnson & Johnson, historical P/OP calculation (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Operating earnings (in millions)
Operating profit per share2
Share price1, 3
Valuation Ratio
P/OP ratio4
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Operating profit per share = (Operating earningsQ4 2025 + Operating earningsQ3 2025 + Operating earningsQ2 2025 + Operating earningsQ1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.

4 Q4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

5 Click competitor name to see calculations.


The Price to Operating Profit (P/OP) ratio exhibited fluctuations over the observed period, spanning from April 2022 to December 2025. Initially, the ratio demonstrated a decreasing trend, followed by periods of relative stability and subsequent increases. A general observation suggests a potential correlation between share price movements and operating profit per share, though the relationship isn't consistently linear.

Initial Decline (Apr 3, 2022 – Dec 31, 2022)
The P/OP ratio decreased from 21.06 in April 2022 to 17.62 by the end of 2022. This decline coincided with a decrease in share price from US$180.46 to US$158.24, while operating profit per share remained relatively stable, suggesting the price decrease was the primary driver of the ratio’s reduction.
Fluctuation and Recovery (Apr 2, 2023 – Oct 1, 2023)
The first half of 2023 saw a slight increase to 18.91 in July, followed by a significant drop to 15.69 in October. This period was characterized by volatility in the share price, decreasing from US$163.70 to US$145.60. Operating profit per share also experienced a slight decline during this timeframe.
Subsequent Increases (Dec 31, 2023 – Dec 28, 2025)
From December 2023 through December 2025, the P/OP ratio generally increased, culminating in a value of 22.95. This upward trend was largely driven by a substantial increase in share price, rising from US$156.55 to US$240.86, coupled with a corresponding increase in operating profit per share from US$8.80 to US$10.49. The most significant increase in the ratio occurred between September 2025 (19.83) and December 2025 (22.95).
Recent Stability (Jun 30, 2024 – Sep 28, 2025)
Between June 2024 and September 2025, the P/OP ratio remained relatively stable, fluctuating between 17.54 and 19.83. This suggests a period where share price and operating profit per share moved in a correlated manner, maintaining a consistent valuation relationship.

Overall, the P/OP ratio demonstrates sensitivity to changes in both share price and operating profit per share. The observed increases in the ratio towards the end of the period suggest a growing investor confidence or potentially increased market expectations regarding future profitability.


Price to Sales (P/S)

Johnson & Johnson, historical P/S calculation (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Sales to customers (in millions)
Sales per share2
Share price1, 3
Valuation Ratio
P/S ratio4
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
Sales per share = (Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025 + Sales to customersQ1 2025) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.

4 Q4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

5 Click competitor name to see calculations.


The price-to-sales ratio exhibited fluctuations over the observed period, spanning from April 2022 to December 2025. An initial decline was followed by periods of relative stability and subsequent increases, culminating in a notably higher ratio at the end of the period.

Initial Decline (Apr 3, 2022 – Oct 1, 2022)
The price-to-sales ratio decreased from 5.00 in April 2022 to 4.01 by October 2022. This suggests a relative decrease in the valuation assigned to each dollar of sales during this timeframe, potentially influenced by market conditions or investor sentiment.
Fluctuation and Stabilization (Oct 2, 2022 – Sep 28, 2025)
Following the initial decline, the ratio experienced volatility, moving between approximately 4.01 and 4.84 through July 2023. A period of relative stability then emerged, with the ratio fluctuating between 4.19 and 5.04 from December 2023 to September 2025. This indicates a period where the market valuation, relative to sales, remained within a constrained range.
Significant Increase (Dec 28, 2025)
A substantial increase in the price-to-sales ratio was observed in December 2025, reaching 6.16. This represents the highest ratio recorded within the analyzed period and suggests a significant shift in market valuation, potentially driven by increased investor confidence or expectations of future sales growth.
Sales per Share Trend
Sales per share generally increased over the period, moving from 36.06 in April 2022 to 39.09 in December 2025. This upward trend in sales per share occurred concurrently with the fluctuations in the price-to-sales ratio, influencing the overall valuation metric.
Overall Trend
Despite interim fluctuations, the price-to-sales ratio demonstrated an overall increasing trend when comparing the beginning and end of the period. The ratio increased from 5.00 in April 2022 to 6.16 in December 2025, indicating a higher valuation relative to sales at the end of the observation window.

Price to Book Value (P/BV)

Johnson & Johnson, historical P/BV calculation (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1
Selected Financial Data (US$)
Total Johnson & Johnson shareholders’ equity (in millions)
Book value per share (BVPS)2
Share price1, 3
Valuation Ratio
P/BV ratio4
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q4 2025 Calculation
BVPS = Total Johnson & Johnson shareholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.

4 Q4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

5 Click competitor name to see calculations.


The price-to-book value (P/BV) ratio exhibited fluctuations over the observed period, spanning from April 2022 to December 2025. Initially, the ratio demonstrated a slight decline from 6.36 to 6.01, followed by a period of relative stability around the 6.0 range before decreasing to 5.37 by the end of 2022.

Initial Decline and Stabilization (Apr 2022 - Dec 2022)
The P/BV ratio began at 6.36 in April 2022 and decreased to 5.37 by December 2022. This suggests a potential shift in investor sentiment regarding the company’s valuation relative to its net asset value during this period. The initial decrease was modest, indicating a gradual adjustment.

The first half of 2023 saw a rebound, with the P/BV ratio increasing to 5.79 in July 2023. However, a more substantial decline followed in the latter half of the year, reaching a low of 4.92 in October 2023. A partial recovery occurred, closing the year at 5.48. Throughout 2024, the ratio remained relatively stable, fluctuating between 5.20 and 5.69.

Volatility in 2023
The year 2023 was characterized by increased volatility in the P/BV ratio. The decline to 4.92 in October 2023 represents the lowest point in the observed period, potentially reflecting market concerns or specific company-related events. The subsequent recovery suggests a reassessment of the company’s value.

A significant upward trend emerged in 2025. The P/BV ratio increased steadily from 4.79 in March 2025 to 7.12 in December 2025, representing a substantial increase in valuation relative to book value. This suggests growing investor confidence or a change in market perception of the company’s future prospects.

Significant Increase in Late 2025
The substantial increase in the P/BV ratio during the final quarters of 2025 is a notable observation. This could be attributed to positive company performance, favorable market conditions, or anticipation of future growth. The ratio reached 7.12, the highest value recorded within the analyzed timeframe.

Throughout the period, the book value per share demonstrated a generally increasing trend, though with some quarterly variations. This upward trend in book value likely contributed to the overall changes observed in the P/BV ratio.

Book Value Per Share Trend
Book value per share generally increased from US$28.39 in April 2022 to US$33.84 in December 2025. This indicates a growth in the company’s net asset value over time, which would naturally influence the P/BV ratio when considered in conjunction with share price movements.